Skip to main content

SARS-CoV-2 Nucleocapsid Antibody (1C7C7) - Azide and BSA Free

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-07043

Recombinant Monoclonal Antibody
Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NBP3-07043

Key Product Details

Species Reactivity

SARS-CoV-2

Applications

ELISA, Immunohistochemistry, Western Blot

Label

Unconjugated

Antibody Source

Recombinant Monoclonal Mouse IgG2A Clone # 1C7C7

Format

Azide and BSA Free

Concentration

1 mg/ml

Product Specifications

Immunogen

Recombinant nucleoprotein of SARS-CoV (severe acute respiratory syndrome).The nucleocapsid protein is expressed in the internal nucleocapsid of SARS-CoV-2.

Specificity

This antibody specifically targets an epitope on the SARS-CoV-2 and SARS-CoV nucleocapsid protein. This antibody does not cross-react with the nucleocapsid of other common human coronaviruses, OC43 and 229E

Clonality

Monoclonal

Host

Mouse

Isotype

IgG2A

Scientific Data Images for SARS-CoV-2 Nucleocapsid Antibody (1C7C7) - Azide and BSA Free

N/A: SARS-CoV-2 Nucleocapsid Antibody (1C7C7) [NBP3-07043] - Exp1293 cells were transfected with expression plasmid coding for SARS-CoV-2 Nucleocapsid and incubated for 48 hours. Cells were permeabilized, incubated with dilutions of supernatant collected from cells transfected with DNA plasmids coding for the heavy and light chains of 1C7 and binding identified by the addition of goat anti-mouse IgG FITC.
SARS-CoV-2 Nucleocapsid Antibody (1C7C7) - Azide and BSA Free

Western Blot: SARS-CoV-2 Nucleocapsid Antibody (1C7C7) - Azide and BSA Free [NBP3-07043] -

Western Blot: SARS-CoV-2 Nucleocapsid Antibody (1C7C7) - Azide and BSA Free [NBP3-07043] - Lysates were derived from A549 cells (Transduced with ACE2 by adenoviral vector), mock vs. SARS-CoV-2-infected MO12, 24 hours, with 60ug of lysates loaded/lane, Image Courtesy of Jeff Johnson Laboratory, ISMMS.
SARS-CoV-2 Nucleocapsid Antibody (1C7C7) - Azide and BSA Free

Immunocytochemistry/ Immunofluorescence: SARS-CoV-2 Nucleocapsid Antibody (1C7C7) - Azide and BSA Free [NBP3-07043] -

Immunocytochemistry/ Immunofluorescence: SARS-CoV-2 Nucleocapsid Antibody (1C7C7) - Azide and BSA Free [NBP3-07043] - Vero E6 infectedcwith SARS-CoV-2, Wa-1 @ MOI = 0.1 for 48 hours. Cells were fixed with 4 % formaldehyde (4hr), perm 0.1% Triton X (15min), blocked with 4 % BSA, 1:1000 diluted with clone 1C7C7 (Anti-SARS-CoV-2 Nucleocaspid) O/N tehn 1:1000 anti-mouse Dylight 488 (1 hour), Image Courtesy of Dr. Ana Fernandex - Sesma Laboratory, ISMMS.

Applications for SARS-CoV-2 Nucleocapsid Antibody (1C7C7) - Azide and BSA Free

Application
Recommended Usage

ELISA

Optimal dilutions of this antibody should be experimentally determined.

Immunohistochemistry

Optimal dilutions of this antibody should be experimentally determined.

Western Blot

Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A purified

Formulation

0.01 M PBS (pH 7.2 - 7.4), 150 mM NaCl

Format

Azide and BSA Free

Preservative

No Preservative

Concentration

1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -80C long term. Avoid freeze-thaw cycles.

Background: SARS-CoV-2 Nucleocapsid

The SARS-CoV-2 Nucleocapsid protein is one of the four major structural proteins of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of COVID-19 (1,2). The nucleocapsid protein is an RNA-binding protein that is essential for viral assembly into a ribonucleoprotein complex and also functions in viral budding (2,3). More specifically, after viral replication and RNA synthesis, the viral genomes that are encapsulated by the nucleocapsid protein will bud into the membrane and help with mature virus formation (2). The nucleocapsid protein is synthesized as 419 amino acids (aa) in length with a theoretical molecular weight of 45.6 kDa (4). Structurally, the nucleocapsid protein contains an RNA-binding domain (N1b), a dimerization domain (N2b), and a few shorter regions (N1a, N2a, and spacer B/N3) (3). It is the N1b domain that is suggested to be involved in RNA binding (3). The nucleocapsid N1b domain contains a beta-hairpin, a loop region, and a beta-sheet core, giving it a right-handed shape (3). Conversely, the N2b domain functions in dimerization which promotes assembly into a helical filament where the dimer interface is made of two beta-strands and an alpha-helix portion (3). Inhibition of nucleocapsid assembly may be a potential target for treating COVID-19 infection.

Following SARS-CoV-2 infection, B cells and T cells display an immune response against nucleocapsid protein and nucleocapsid-specific neutralizing antibodies are produced (5). Interestingly, a study of patients who have recovered from COVID-19 revealed that there were no neutralizing antibodies against nucleocapsid protein present; however, a high presence against neutralizing spike RBD antibodies were detected (5).

References

1. Pillay T. S. (2020). Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. Journal of Clinical Pathology. https://doi.org/10.1136/jclinpath-2020-206658

2. Malik Y. A. (2020). Properties of Coronavirus and SARS-CoV-2. The Malaysian Journal of Pathology.

3. Zhu, G., Zhu, C., Zhu, Y., & Sun, F. (2020). Minireview of progress in the structural study of SARS-CoV-2 proteins. Current Research in Microbial Sciences. https://doi.org/10.1016/j.crmicr.2020.06.003

4. Uniprot (P0DTC9)

5. Shah, V. K., Firmal, P., Alam, A., Ganguly, D., & Chattopadhyay, S. (2020). Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2020.01949

Alternate Names

2019-nCoV N Protein, 2019-nCoV Nucleocapsid Protein, COVID-19 N protein, COVID-19 nucleocapsid protein, Human coronavirus Nucleoprotein, nucleocapsid phosphoprotein, Nucleocapsid protein, Nucleoprotein, ORF9; structural protein, SARS-CoV-2, SARS-CoV-2 Nucleocapsid protein, SARS-CoV-2 N protein, SARSCoV2 Nucleoprotein, Severe Acute Respiratory Syndrome Coronavirus 2 Nucleocapsid Protein

Gene Symbol

N

Additional SARS-CoV-2 Nucleocapsid Products

Product Documents for SARS-CoV-2 Nucleocapsid Antibody (1C7C7) - Azide and BSA Free

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for SARS-CoV-2 Nucleocapsid Antibody (1C7C7) - Azide and BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...